Company attributes
Other attributes
Brooklyn ImmunoTherapeutics is a clinical stage biopharmaceutical company that is focused on exploring the role that cytokine-based therapies can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer treatments.
The company's leading product candidate is IRX-2, a cytokine based therapy. It delivers IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, thereby enabling the immune system to attack cancer cells. In a Phase 2A clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which is associated with a survival benefit in patients with head and neck cancer. Brooklyn ImmunoTherapeutics has initiated a Phase 2B clinical study of IRX-2 in patients with squamous cell cancer of the head and neck, with results expected to be reported in 2020.
The company is also exploring the potential of IRX-2 in other oncology indications in collaboration with multiple pharmaceutical companies. Clinical trials in combination with other anti-cancer agents such as checkpoint inhibitors are also being conducted.
